Bifunctional ShRNAimPDX-1 Therapy Prevents Hypoglycemic Death From Insulinoma in Mice Abstract #502

Introduction: PDX-1 is a novel molecular target for insulinoma. Bi-functional shRNAi platform has been developed that results in a more effective targeted gene knockdown.
Aim(s): Using bi-shRNAimPDX-1 therapy in a mouse model of metastatic insulinoma to determine whether PDX-1 is a therapeutic target for insulinoma.
Materials and methods: Insulinoma (ß TC-6) cell proliferation and insulin secretion in vitro were determined by MTS and ELISA assay after bi-shRNAimPDX-1. In vivo therapy was performed on an i.p. ß TC-6 SCID mouse model with three bi-weekly cycles of iv liposomal(L)- bi-shRNAimPDX-1. Glucose and insulin levels and expression of islet cell PDX-1, insulin, PP levels, apoptosis and cell cycle proteins were determined. Survival analysis was performed using Kaplan-Meier (p<0.05).
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr F Charles Brunicardi

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1161 Comparative Proteomic Analysis of Human Insulinoma and Its Clinical Implications in Pancreatic Neuroendocrine Tumors
Introduction: Insulinoma is the most common functional PNET. Its molecular tumorigenesis is largely unknown and proteomic study on insulinoma has not been reported
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Dr Yuan-Jia Chen
Authors: Qiao X W, Song Y L, Bai C M, Zhu L M, ...
#319 Expression of EGFR and IGF Pathway Genes in Insulinomas
Introduction: Anti-epidermal growth factor receptor (EGFR) therapy has been suggested in patients with inoperable/progressive endocrine pancreatic tumors (EPTs). However, various % EGFR-expressing EPTs are reported.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Ernst-Jan M Speel
#727 Serum Levels of Chromogranin A Were Not Elevated in Patients with Insulinomas
Introduction: According to ENETS and NANETS Consensus Guidelines, Chromogranin A (CgA) is the most practical and useful serum tumor marker in NET patients (pts), including pancreatic NETs. Many studies suggested that test of blood CgA should be mandatory for NET diagnosis.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr. X-W Qiao
Authors: Qiao X W, Qiu L, Liu B, Song Y L, ...
#72 Reduced expression of p27 and the occurrence of CpG island methylator phenotype in insulinomas
Introduction: The molecular pathogenesis of sporadic insulinoma is unclear, though some of the genes were found to be slienced by promoter methylation. CpG island methylator phenotype (CIMP) was found in a number of common tumors and correlated with loss of expression of p27, which may contribute to the tumorigenesis of the tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Yuan-Jia Chen
Authors: Chen Y J, Zhou Q, Xiao Y, Zhu Y, ...
#978 Prognostic Value of Somatostatin Receptor Scintigraphy on High-Grade Neuroendocrine Neoplasms and Impact on the Treatment Decision of Intermediate-Grade Neuroendocrine Neoplasms
Introduction: Somatostatin receptor scintigraphy (SRS) could detect not only somatostatin receptors but also tumor images in patients with neuroendocrine neoplasms (NENs).
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Professor Jian Ming Xu
Authors: Jia R, Fu Y L, Lin L, Wang Y, ...
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.